Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025

Supplementary Figure S3 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiyi WangYZYu ZhangXLXiangdong Li

Discussion

Loading...

Member takes

Overview

Observational analysis reveals that myeloid Trem2 influences apoptotic neutrophil levels in NASH, suggesting potential for improved checkpoint immunotherapy.

Key Points

  • Lack of myeloid Trem2 leads to increased apoptotic neutrophil accumulation in NASH liver, affecting immune response.
  • The presence of myeloid Trem2 was linked to a reduced immunosuppressive niche in NASH-driven liver conditions.
  • Checkpoint immunotherapy effectiveness may improve by targeting myeloid Trem2 to alter the immune landscape in hepatocarcinogenesis.
  • These findings indicate a potential new avenue for enhancing immunotherapy strategies in NASH-related liver cancer.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219a4https://doi.org/10.1158/2326-6066.30255487
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S1 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  2. 2Supplementary Figure S2 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  3. 3Supplementary Figure S7 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  4. 4Supplementary Figure S4 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  5. 5Supplementary Figure S5 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025